Drugs / NBP608
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03114982 | May → Jul 2016 | chickenpox | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03116594 | Jan → Apr 2014 | herpes zoster | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT07415252 | Jul 2026 → Feb 2027 expected | chickenpox | SK Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT03114943 | Jul 2016 → Jun 2017 | chickenpox | SK Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03120364 | Sep → Dec 2015 | herpes zoster | SK Chemicals Co., Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBP608 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03120364 ↗ |
| Modality | Vaccine | “each subject is administered with single dose of vaccine which is randomly assigned” NCT03116594 ↗ |
| Route | Subcutaneous | “by subcutaneous injection” NCT03114982 ↗ |